Therapy for Mycobacterium kansasii Infection: Beyond 2018

Abstract excerpt

The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300mg/day), rifampin (600mg/day), and ethambutol (15mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in this regimen. The contribution of isoniazid is unclear since its in vitro MICs against M. kansasii are near the peak achievable serum levels and more than 100-fold...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mycobacterium research and diagnosis
• Share to Quinazolinone synthesis and applications
• Share to Tuberculosis Research and Epidemiology